XRAY

DENTSPLY SIRONA INC

Healthcare | Small Cap

$0.33

EPS Forecast

$859

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Dentsply Sirona’s Q3 2026: Wellspect Runs Hot, Surity Joins the Portfolio Parade

XRAY, the Dentsply Sirona ticker, delivered a Q3 2026 that looked more like a sprint than a stumble. Net sales clocked in at $836 million, a figure that refuses to be swept away by the usual quarterly noise. GAAP gross margin stood at 52.9%, with GAAP diluted earnings per share of ($0.01). The company countered with a robust set of non-GAAP metrics—adjusted gross margin of 54.5%, adjusted EBITDA margin of 17.3%, and adjusted earnings per share of $0.29—an arrangement that makes a decent case for readers who care about underlying profitability rather than raw GAAP headwinds. All of this sits atop a narrative the company has been preaching for a while: a Return-to-Growth Action Plan is starting to translate into actual market momentum.

Key numbers at a glance

  • Net Sales: $836 million (Q3 2026)
  • GAAP gross margin: 52.9%; GAAP diluted EPS: ($0.01)
  • Adjusted gross margin: 54.5%; Adjusted EBITDA margin: 17.3%; Adjusted EPS: $0.29
  • Wellspect Healthcare: record quarterly sales, 10.1% as-reported growth
  • Surity Urinary Management System portfolio: near launch in the U.S.; expansion activity highlighted
  • FY2026 guidance: net sales ~ $3.5 billion; adjusted EPS of $1.20–$1.30
  • Inventory adjustment: a $39 million benefit from refining the estimate to eliminate unrealized profit in inventory; reduces reported net loss and increases adjusted net income by ~ $30 million; not expected to recur

What the numbers say about the plan

Reading the press release like a memo from a deck that won’t quit, the highlights are less about a single blockbuster product and more about a portfolio approach. Wellspect Healthcare posted a record quarter, with roughly 10.1% in as-reported growth, signaling that specialty devices can still drive durable top-line gains even when the macro environment is imperfect. The Surity Urinary Management System—no longer a twinkle in a product manager’s eye—appears to be advancing toward the U.S. rollout, a signal that Dentsply Sirona is leaning into lifecycle-based offerings rather than one-off wins.

Guidance, one-off adjustments, and what to watch

The company updated its FY2026 outlook to approximately $3.5 billion in net sales and an adjusted EPS range of $1.20 to $1.30. That creates a clean reading for the street on the revenue forecast and the trajectory of earnings. The 39 million dollar benefit from the refinement of the estimate to eliminate unrealized profit in inventory is a notable one-off item—the kind of adjustment that helps the quarter look cleaner but raises questions about recurring effects. Dentsply cautions that this impact is not expected to recur, which matters for analysts poring over the long-run earnings framework. Analysts will be comparing XRAY’s adjusted EPS to the EPS consensus and weighing whether the current trajectory can be sustained as the company scales the Wellspect and Surity franchises.

What it portends for XRAY peers and the sector

Internally, the shift toward growth segments—specialty devices, advanced endodontics, and U.S. dealer expansion—reads as a template for other dental- and medtech-focused players wrestling with inflationary pressures and uneven demand. The emphasis on blended margins—managing cost with a higher-margin services/portfolio mix—could set a precedent for peers to articulate clearer revenue forecasts and push toward a more explicit EPS consensus narrative. In short, Dentsply Sirona’s Q3 demonstrates that you can pursue “growth” with discipline, and that the market will reward (or punish) the clarity of the path to profitability as much as the size of the profits themselves.

Analyst lens and strategic inch-by-inch progress

From a finance writer’s perch, the inventory adjustment looks like a rare honest error correction—one that moves the numbers toward a more meaningful presentation of the business. The Wellspect outperformance and the Surity portfolio’s U.S. momentum are the kinds of data points that, if sustained, could push the company’s revenue forecast higher and push the EPS consensus toward more optimistic levels. The question for investors is whether this momentum can be translated into durable earnings power given competitive dynamics and the healthcare spending backdrop.

Bottom line

Q3 2026 for Dentsply Sirona confirms that the Return-to-Growth plan is moving from slideware to runway. A solid top-line backdrop, an improving margin profile on adjusted metrics, and a strategic push into Wellspect and Surity suggest the company can translate its growth narrative into steady earnings power. For XRAY peers and the broader dental/medtech cohort, the takeaway is pragmatic: clarity in revenue forecast and a credible path to EPS consensus matter as much as the headline numbers themselves. In the world of corporate finance, that balance might just be the rarest product of all—and this quarter, Dentsply Sirona seems to be selling it with a straight face and a steady hand.

Keywords: XRAY, EPS, earnings surprise, EPS consensus, revenue forecast, net sales, adjusted EPS, Wellspect, Surity, FY2026 guidance.